Company news

Dyadic International, Inc. news in 2022

Dyadic International, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

November 9, 2022

Dyadic to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022

October 26, 2022

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

October 26, 2022

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

October 3, 2022

Dyadic Reports Second Quarter 2022 Financial Results and Highlights Recent Company Developments

August 9, 2022

Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

July 26, 2022

Dyadic Announces Research, License and Collaboration for the Manufacture of Animal Free Ingredients

May 10, 2022

Dyadic Announces Successful Toxicology Data Published in “Toxicologic Pathology”

May 8, 2022

Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

April 27, 2022

Dyadic Reports 2021 Year End Results and Recent Company Progress

March 28, 2022

Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

February 9, 2022

Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process

January 19, 2022

Calls in 2022

Decks in 2022